Tibau, A, Romano, A, Liu, ITT, Han, J, Cliff, ERS, Kesselheim, AS. Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(10)DOI:10.1093/jnci/djaf195. PMID:40690366. IF:7.200(Q1/2D).

López-Fernández, A, Pardo, M, Pérez-Ballestero, E, Darder, E, Alfonso, R, Torres-Esquius, S, Garcés, VN, Cajal, TRY, Brunet, J, Balmaña, J. Exploring communication preferences for disclosing breast cancer risk in women with a family history. Journal of Genetic Counseling. 2025; 34(5)DOI:10.1002/jgc4.70114. PMID:40965181. IF:1.900(Q2/5D).

Ospina-Serrano, AV, González-Larriba, JL, Nadal, E, Trancho, FH, Bosch-Barrera, J, Calvo, V, Bolufer-Nadal, S, de la Cruz, JLCC, Macía-Vidueira, I, Alvarez-Kindelán, A, Del Barco-Morillo, E, Bernabé-Caro, R, Casal-Rubio, J, Cilleruelo-Ramos, A, Cobo-Dols, M, Dómine-Gómez, M, Figueroa-Almánzar, S, Insa-Mollá, A, Jarabo-Sarceda, JR, Jiménez-Maestre, U, López-Castro, R, Majem, M, Martinez-Marti, A, Téllez, EM, Sánchez-Lorente, D, López-Valcárcel, M, Couñago, F, Garcia-Campelo, R, de Castro, J, Massuti-Sureda, B, Provencio, M. Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Translational Lung Cancer Research. 2025; 14(9)DOI:10.21037/tlcr-2025-619. PMID:41132973. IF:3.500(Q1/3D).

Di Maio, M, Gonzalez-Billalabeitia, E, Marandino, L, Maroto, P, Timsit, MO, Luccarini, I, Robinson, P, Van Sanden, S, Hadaschik, BA. A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer. Frontiers in Oncology. 2025; 15DOI:10.3389/fonc.2025.1468928. PMID:41059299. IF:3.300(Q2/4D).